RxDoctor Payments Data

Karen Blindauer, MD

Neurology · Milwaukee, WINPI 1699726034

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 5 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Medtronic accounts for 61.5% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for neurology clinicians in WI, where the typical reported total is $205.

$136in general payments, 2019–2025

Across 5 payments — averaging $27.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$83
  • Abbott$52
$269,803in research payments, 2019–2025

Across 3 payments — averaging $89,934 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Biogen$270K

What the payments were for

  • Food & beverage$136100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic3$83
Abbott2$52

How this compares

$136 in reported general payments places this provider in the 40th percentile of 308 neurology providers in Wisconsin.

See all neurology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$59,737
Medicare patients
316
Services billed
874

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RytaryCarbidopa/Levodopa196$375,664
NuplazidPimavanserin Tartrate31$194,599
GocovriAmantadine Hcl14$60,286
Carbidopa-LevodopaCarbidopa/Levodopa1,167$52,940
NeuproRotigotine26$49,513
Carbidopa-Levodopa ErCarbidopa/Levodopa453$37,083
AmantadineAmantadine Hcl411$28,094
OngentysOpicapone27$24,596
Entacapone70$13,944
Ropinirole ErRopinirole Hcl28$10,442
Rasagiline Mesylate41$9,574
Primidone196$7,898
Emgality PenGalcanezumab-Gnlm11$7,817
Pramipexole DihydrochloridePramipexole Di-Hcl188$6,144
Pramipexole ErPramipexole Di-Hcl12$5,313

Paid to pharmacies, not to this prescriber.

Other neurology in Milwaukee

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →